Deals
Bristol-Myers Poised to Close Celgene Deal After U.S. Nod
- FTC approves $74 billion deal with sale of psoriasis drug
- Bristol-Myers said it expects to close the purchase Nov. 20
This article is for subscribers only.
Bristol-Myers Squibb Co. won U.S. antitrust approval for its acquisition of Celgene Corp., the last regulatory approval needed for the blockbuster pharmaceutical deal.
The Federal Trade Commission signed off on the tie-up after Bristol-Myers earlier this year agreed to sell one of Celgene’s most lucrative drugs to resolve concerns the deal would otherwise harm competition, the agency said Friday. Bristol-Myers said it expects to close the purchase Nov. 20.